金宇生物技术股份有限公司修订拟回购注销2023年员工持股计划部分股票数量的公告
要点摘要
- 公司董事会于2026年4月22日召开会议，审议通过了关于回购注销2023年员工持股计划部分股票的议案。
- 由于相关人员变动及业绩考核未达成，公司修订了拟回购注销的股票数量。
- 首次授予部分股票回购注销数量由906.89万股下调至851.84万股。
- 回购专用证券账户中使用期限满三年的回购股份330.16万股拟注销。
- 本次回购注销价格为6.23元/股。
- 公司股本将发生变动，注册资本由人民币1,111,747,826元变更为1,099,927,826元（或1,099,377,326元，视最终数据而定）。
- 相关公司章程同步修订，全部为普通股。
- 议案尚需提交股东会审议，最终以中国证券登记结算公司上海分公司出具的证券变更登记表为准。
详细内容
金宇生物技术股份有限公司（生物股份，证券代码：600201）于2026年4月22日召开第十二届董事会第五次会议，审议通过了《关于拟回购注销2023年员工持股计划部分股票及注销回购专用证券账户中部分股票的议案》和《关于修订<公司章程>及其他制度的议案》。公司于2026年4月23日已在上海证券交易所网站披露相关公告。
由于公司相关人员变动和业绩考核未达成，经核查中国证券登记结算有限责任公司系统数据，公司对2023年员工持股计划部分股票拟回购注销数量进行了修订：
- 首次授予部分股票回购注销数量由原公告的906.89万股调整为851.84万股。
- 回购专用证券账户中使用期限满三年的回购股份330.16万股拟注销。
主要原因包括：
- 首次授予部分第三个解锁期公司层面业绩考核未达成，解锁条件未成就，对应未解锁权益份额不得解锁。
- 11名持有人因个人原因离职，不再具备员工持股计划持有人资格，其对应未解锁份额不得解锁。
回购注销价格为6.23元/股。回购注销后，公司股份总数将减少，股本结构发生变动：
- 注销前股份总数：1,111,747,826股。
- 注销后股份总数：1,099,927,826股（或1,099,377,326股，视最终数据以证券登记公司为准）。
- 全部为普通股。
公司章程中“公司注册资本”“已发行股份数”等条款将同步修订，反映股本变更。
对投资者的影响及重要提示
- 本次回购注销为公司员工持股计划及回购股份的调整，直接影响公司总股本和注册资本。
- 股本减少可能对每股收益、每股净资产等指标产生积极影响，理论上有利于提升股东价值。
- 本次议案尚需提交公司股东会审议，最终股本变动以中国证券登记结算公司出具的登记表为准。
- 如股东会未通过或出现其他变动，相关事项可能会调整。
- 此次回购注销属于重要公司事项，可能对公司股价产生影响，投资者需密切关注后续公告。
免责声明
本文内容仅供参考，不构成任何投资建议。投资者应根据自身情况和风险偏好，结合公司公告及相关法律法规，进行独立判断和决策。公司最终股本变动以中国证券登记结算公司上海分公司出具的证券变更登记表为准。
Jinyu Biotechnology Co., Ltd. Revises Number of Shares to be Repurchased and Cancelled Under 2023 Employee Stock Ownership Plan
Key Highlights
- The board meeting on April 22, 2026, approved the revised plan to repurchase and cancel part of the shares under the 2023 Employee Stock Ownership Plan (ESOP).
- Due to personnel changes and unmet performance targets, the number of shares to be repurchased and cancelled has been revised.
- The number of shares to be repurchased and cancelled was reduced from 9.0689 million to 8.5184 million.
- 330.16 million shares held in the special repurchase account for over three years are also planned to be cancelled.
- The repurchase price is set at RMB 6.23 per share.
- After the repurchase and cancellation, the company’s registered capital will decrease from RMB 1,111,747,826 to RMB 1,099,927,826 (or 1,099,377,326 depending on final data).
- The articles of association will be revised to reflect the new share capital, all ordinary shares.
- The resolutions are subject to shareholder approval; final changes depend on China Securities Depository and Clearing Corporation Shanghai Branch records.
Details
Jinyu Biotechnology Co., Ltd. (ticker: 600201) convened its 12th Board, 5th meeting on April 22, 2026, and approved the plan to repurchase and cancel part of the shares under the 2023 ESOP, as well as amend the articles of association and related regulations. The company disclosed these announcements on the Shanghai Stock Exchange website on April 23, 2026.
Due to personnel changes and unmet company-level performance targets, the company revised the number of shares planned for repurchase and cancellation after checking with the China Securities Depository and Clearing Corporation system:
- The number of shares for repurchase and cancellation under the initial ESOP grant was reduced from 9,068,900 to 8,518,400.
- Shares held in the special repurchase account for over three years amounting to 3,301,600 will also be cancelled.
Reasons include:
- The third unlocking period of the ESOP failed to meet performance assessment requirements, so related shares cannot be unlocked and will be repurchased and cancelled.
- 11 ESOP participants left the company, losing eligibility, so their shares will also be repurchased and cancelled.
Repurchase price is RMB 6.23 per share. After repurchase and cancellation:
- Total shares before cancellation: 1,111,747,826.
- Total shares after cancellation: 1,099,927,826 (or 1,099,377,326, subject to final confirmation).
- All shares are ordinary shares.
The articles of association will be amended to update the registered capital and issued shares accordingly.
Investor Implications & Price Sensitivity
- This repurchase and cancellation directly impacts the company’s total share capital and registered capital.
- A reduction in share capital may positively affect per-share metrics like EPS and NAV, theoretically enhancing shareholder value.
- Final approval depends on the shareholder meeting and confirmation by China Securities Depository and Clearing Corporation.
- If the shareholder meeting does not approve, or if there are other changes, the plan may be adjusted.
- As a significant corporate event, this repurchase and cancellation may affect the share price; investors should monitor further announcements closely.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should make independent decisions based on their own circumstances, risk preferences, and official company disclosures. Final share changes are subject to confirmation by China Securities Depository and Clearing Corporation.
